Use of Dipeptidyl Peptidase-4 Inhibitors in a Subset of Patients with Cystic Fibrosis Related DiabetesAnery Patel1*, Heather Spain2 and Whitney Goldner1
- *Corresponding Author:
- Anery Patel
Endocrinology Fellow, Department of Internal Medicine
Division of Diabetes, Endocrinology and Metabolism
984120 Nebraska Medical Center, Omaha, Nebraska, USA
E-mail: [email protected], [email protected]
Received date: October 28, 2014; Accepted date: February 21, 2015; Published date: February 25, 2015
Citation: Patel A, Spain H, Goldner W (2015) Use of Dipeptidyl Peptidase-4 Inhibitors in a Subset of Patients with Cystic Fibrosis Related Diabetes. J Diabetes Metab 6:501. doi: 10.4172/2155-6156.1000501
Copyright: © 2015 Patel A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cystic Fibrosis Related Diabetes (CFRD) is the most common comorbidity in patients with Cystic Fibrosis (CF) and its incidence is rising. CFRD is associated with a decline in clinical status and six-fold increased mortality in patients with CF, the outcomes of which can be improved with early diagnosis and proper treatment. While current treatment guidelines recommend the use of insulin monotherapy to treat CFRD and do not recommend oral agents, these guidelines were published before the use of dipeptidyl peptidase-4 inhibitors (DPP-4). We present two cases of CFRD patients who were successfully managed with DPP-4 inhibitors both inpatient as well as outpatient.